SCHEMBL3772059

SCHEMBL3772059

Fc1cccc(-c2csc(C3CCNCC3)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.64
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
KDM4E B2RXH2 2/20 0.54
MAPT P10636 1/20 0.54
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
PLAT P00750 2/20 0.42
TRPV1 Q8NER1 1/20 0.41
MAP4K3 Q8IVH8 1/20 0.40
POLB P06746 1/20 0.40
WNT1 P04628 1/20 0.40
TGFBR1 P36897 1/20 0.40
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PDE3B Q13370 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2986096 0.99 HPGDS (0.62) HPGDSMEN1KMT2AKDM4EMAPT
SCHEMBL19399148 0.90 KDM4E (0.60) HPGDSMEN1KMT2AKDM4EMAPT
SCHEMBL10040499 0.84 HPGDS (0.60) HPGDSMEN1KMT2AMAPTALDH1A1
SCHEMBL4261299 0.84 MEN1 (0.60) HPGDSMEN1KMT2AKDM4EALDH1A1
SCHEMBL3772350 0.83 HPGDS (0.59) HPGDSMEN1KMT2AKDM4EALDH1A1
SCHEMBL2297392 0.83 HPGDS (0.78) HPGDSMEN1KMT2AKDM4EMAPT
SCHEMBL4258842 0.83 HPGDS (0.55) HPGDSMEN1KMT2AKDM4EALDH1A1
Bromide SCHEMBL2982781 0.83 MEN1 (0.59) HPGDSMEN1KMT2AKDM4EALDH1A1
SCHEMBL4260528 0.82 HPGDS (0.58) HPGDSMEN1KMT2AALDH1A1SMN1; SMN2
Bromide SCHEMBL2973216 0.82 HPGDS (0.76) HPGDSMEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
EP-1945635-B1 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-05-06 EP disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
CN-101243078-A Thiazolyl piperidine derivatives useful as h3 receptor modulators HOFFMANN LA ROCHE (CH) 2008-08-13 CN disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 HPGDS 962/4885MEN1 3363/4885KMT2A 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.